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 The optic nerve (ON) is a central nervous system (CNS)
tract comprised of the axons of retinal ganglion cells (RGCs),
and myelinated by oligodendrocytes. Nonarteritic anterior is-
chemic optic neuropathy (NAION), an infarct of the ON, is
produced by sudden RGC axonal ischemia [1]. NAION is the
major cause of sudden ON-related vision loss in individuals
over 50 years old [2]. NAION clinically resembles other CNS
white matter strokes [3], with isolated dysfunction and physi-
ologically demonstrable deficits [4]. NAION produces RGC
loss and ON gliosis, with sparing of other retinal neurons [3,5].
No currently effective measures exist to prevent or treat this
condition [6].
We  recently reported on a new rodent NAION model
(rAION) [7], which utilizes laser photoactivation of rose Ben-
gal to generate superoxide radicals [8]. These radicals selec-
tively damage ON capillary vascular endothelium, producing
predictable and reproducible levels of isolated ON ischemia.
rAION resembles clinical NAION by many parameters [7,9].
Similar to other CNS strokes, isolated ON stroke produces a
biphasic gene response, with rapid (<1 day) and reactive (>3
days) tissue changes [7,10].
Estrogen is a sex steroid with neuroprotective effects in a
variety of neural insults [11-13]. Women of pre-menopausal
age have a significantly lower incidence of stroke than either
men or post-menopausal women [14,15]; post-menopausal
women have a poorer post-stroke recovery than men [16], and
female animals subjected to ischemia have less overall CNS
damage than males [17], suggesting that circulating estrogen
may be neuroprotective against stroke. Estrogen administra-
tion can modify ischemia-related proteins in neuronal cell
culture [18], and has been shown to be effective in reducing
the area of stroke-related damage in a model of global CNS
ischemia [19]. Estrogen administration can also protect RGCs
following global retinal ischemia [20]. We have identified a
number of genes whose expression is known to be affected by
estrogen administration [21]. We were able to do this by uti-
lizing a microarray-based analysis of retina-expressed genes
at early times (1-3 days) post-rAION in male rats by Affymetrix
array analysis, and confirming expression by both real-time
quantitative polymerase chain reaction and northern analysis
(Bernstein et al, manuscript in preparation). Additionally, we
initially evaluated the effects of estrogen pre-infarct adminis-
tration using a “sighting study” on a small number (n=3) of
animals by serial step-cut sections. These limited data sug-
gested that estrogen could be a potentially useful
neuroprotective agent following RGC axonal ischemia. How-
ever, effective post-stroke neuroprotection remains a problem
that must ultimately be resolved by in-vivo analysis. Thus, we
directly evaluated the neuroprotective effects of estrogen post-
treatment after axonal stroke, utilizing a statistically valid num-
ber of animals and modern stereological analysis [22].
METHODS
Animals:  All animal procedures were approved by the Uni-
versity of Maryland Baltimore institutional animal care and
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1920utilization committee prior to experimentation. Female ova-
riectomized Sprague-Dawley albino rats (105-120 g) were ob-
tained from Charles River animal facility (Charles River, MA).
Animals were kept in the University of Maryland Baltimore
animal facility and were given food and water ad libitum.
rAION induction:  Prior to induction, animals were anes-
thetized using a mixture of ketamine/xylazine (80 mg/4 mg/
kg). A fundus contact lens was placed to visualize the normal
rat retina and ON. rAION was induced in anesthetized ani-
mals using tail vein intravenous injection of RB (2.5 mM).
This was followed by ON laser illumination with a frequency
doubled YAG laser (535 nm; Iridex Corporation; Mountain
View, CA), coupled to a slit-lamp (Haag-Streit; Koeniz, Swit-
zerland). Laser beam diameter was 500 µm/12 s. Previous his-
tological studies have shown that this treatment level produces
an ON lesion, resulting in an isolated 60-75% RGC loss (data
not shown). Pre- and post-induction, all eyes were photo-
graphed through a Haag-Streit slit lamp using an eyepiece
adapter (Edmund Scientific, Barrington, NJ) coupled to a
Nikon D1X at 2.4 mPx, with automatic light correction, and
800 ASA.
Post-optic nerve stroke estrogen treatment:  rAION was
induced in ovariectomized female rats (120-150 g; 75 days
average age at induction). Induction levels were adjusted to
produce a predicted loss of 60-75% RGC loss (data not shown).
Immediately after induction, animals were injected with ei-
ther 50 µg/kg 17-estradiol (Wyeth/Ayerst; Phila, PA) in sesame
oil (n=8 animals) or sesame oil vehicle (n=9 animals). An ini-
tial ‘priming’ dose of 5 mcg/kg was given one day before in-
duction in estrogen treated animals (G. Hoffman, personal
communication).
Retinal ganglion cell-retrograde labeling:  Two weeks
post-induction, animals were anesthetized with 10% chloral
hydrate (3.5 ml/kg), and the skull skin infiltrated with 1%
lidocaine. After skull exposure, 2 µl of 2% fluorogold (Mo-
lecular Probes, Invitrogen; Carlsbad, CA) in 0.9% saline was
stereotactically injected into each side of the pretectum, using
a stereotactic frame with digital readout (Stoelting Corp; Wood
Dale, IL). Two weeks post-injection (28 days post-induction),
animals were euthanized using deep pentobarbital anesthesia,
and perfused with 4% paraformaldehyde-phosphate buffered
saline (PF-PBS). Eyes werer enucleated, and the ON and reti-
nae post-fixed 24 h in 4% PF-PBS. ONs were post-fixed in
paraformaldehyde-glutaraldehyde.
Retinal ganglion cell stereology:  Post-fixed retinas were
flat mounted using fluorescent mounting medium. Retrograde
fluorogold-labeled RGCs were identified using a Nikon Eclipse
E800 compound microscope with a 410 nm excitation filter/
450 nm pass filter cube. We utilized a 20X air objective, of
low numerical aperture, to give a depth of field sufficient to
penetrate the nerve fiber and RGC layers. RGCs were counted
using a computer-driven microscope stage that was, controlled
by an optical fractionator linked to a stereological imaging
package (Stereoinvestigator; Ver.6.0; Microbrightfield, Bio-
science, Williston, VT). Stereological analysis was performed
using the Neuroleucida 6.0 program (Microbrightfield), uti-
lizing a sufficient number of random sites within each defined
region. At least 800 cells, at a minimum of nine sites, were
counted per retina. This is greater than the number required
by the Schmitz-Hof equation for statistical validity [22].
Optic nerve histology:  Fixed ON tissue was impregnated
with uranyl acetate, stained with toluidine blue, and embed-
ded in Epon. One-half micron sections were cut and stained
with toluidine blue. ON sections were photographed using a
Nikon D1X at 2.4 mPx.
RESULTS
 Estrogen does not change the appearance of retina post-
rAION. The intra-ocular portion of the ON (Figure 1A) in a
naive rodent eye is flat against the retina (Figure 1A), with
distinct borders. Rodent AION typically produces ON edema
1 day post induction, followed by edema resolution and even-
tual ON atrophy [7]. The intraocular portion of the ON 2 days
post-rAION induction in estrogen-treated animals (Figure 1B;
same eye as in Figure 1A) and vehicle-treated (Figure 1C)
animals showed IN edema. This was marked by both blurring
of optic disk margins (arrow, Figure 1B), and elevation of the
radial retinal vessels emerging from the ON (arrows; Figure
1C). There were no significant differences in retinal appear-
ance between estrogen- and vehicle-treated induced eyes (n=17
eyes). There were no gross apparent changes in the ONs of
contralateral (naive) eyes (data not shown). ON atrophy was
detectable by post-induction day 21 (Figure 2C), typified by
ON atrophy and pallor in all rAION-induced eyes, regardless
of treatment (Figure 1D).
Post-induction estrogen is not neuroprotective in axonal
stroke:  Fluorogold filled RGCs in non-induced control (na-
ive) animals were distributed across the retinal surface (Fig-
ure 2A, ret). Relatively increased RGC numbers were seen
centrally, closer to the ON (Figure 2A). Post-rAION induc-
tion, a regional loss of fluorogold labeled RGCs were seen in
both estrogen treated (Figure 2B, arrows), and vehicle-treated
(Figure 2C) retinas. There was relative sparing of RGCs in
individual regions (compare inferior quadrant in Figure 2B
and superior quadrant in Figure 2C with quadrants in naive
control; Figure 2A). The loss of fluorogold labeled RGCs were
similar in both vehicle- and estrogen-treated animals (com-
pare Figure 2B and Figure 2C).
RGC axon loss patterns were similar in both rAION-in-
duced vehicle and estrogen-treated animals. This was appar-
ent in low magnification cross-section (Figure 2E,F) compared
with naive control eyes (Figure 2D). Axonal loss was marked
centrally in ONs from both estrogen and vehicle treated ani-
mals, with preservation greatest peripherally (Figure 2E-F; ar-
rowheads). A higher power magnification of the same sec-
tions revealed a loss of individual axons, (compare Figure 2G
with Figure 2H-I), and central scarring. There were regions of
intact, myelinated axons, particularly in the ON periphery (Fig-
ure 2H; arrow). Overall loss of ON axons was similar in both
vehicle controls and estrogen treated animals (compare Fig-
ure 2G with Figure 2H,I). These results suggest that post-stroke
estrogen does not preserve RGCs in a regional fashion, nor
does it provide ON protection against rAION-induced axonal
loss.
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1921Stereological analysis of associated retinal ganglion cell
loss in estrogen and vehicle controls after induction of rodent
anterior ischemic optic neuropathy:  Stereological analysis
revealed an average of 102,500-108,000 RGCs in control
(uninduced) retinas for both estrogen and vehicle groups (Fig-
ure 3, compare control numbers for vehicle-treated and estro-
gen-treated animals). Following rAION, a 25-75% RGC loss
was demonstrable in estrogen treated animals post-infarct as;
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Figure 1. Appearance of estrogen- and vehicle treated retina and optic nerve before and after induction of rodent anterior ischemic optic
neuropathy.  A: Pre-induction. The retina (Retina), optic nerve (ON) and retinal vessels (A and V) are normal in appearance. B: Same eye as
A two days after-rodent anterior ischemic optic neuropathy (rAION) and estrogen treatment. The ON disk margin is blurred and edematous
(arrow). C: rAION-induced+, vehicle-treated eye, two days post-induction. The ON is edematous, demonstrable as an alteration in direction
of the retinal vessels emerging from the ON (arrows). D: ON appearance in estrogen treated animal 21 days post-rAION induction. The ON
disk margin is apparently shrunken, with marked pallor (arrows). The scale bar represents 250 µm.
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Figure 2. Histological comparison of retinal ganglion cells and optic nerves from naive, estrogen-treated, and vehicle treated animals follow-
ing rodent anterior ischemic optic neuropathy induction.  A, D, G are naíve animals, B, E, H are estrogen-treated animals, and C, F, I are
vehicle treated animals. A-C: Distribution of fluorogold labeled retinal ganglion cells (RGC). Retinas from naive controls (A) have fluorogold
labeled RGCs distributed over the retinal surface, with increased RGC numbers near the optic nerve (ON). At 28 days after rodent anterior
ischemic optic neuropathy (rAION) induction, there is a regional loss of labeled RGCs in the estrogen-treated retina (B, arrows), with preser-
vation of RGC distribution in the inferior wing of the retina. A similar regional RGC loss is seen in the retina of vehicle treated animals (C:
arrows). D-F: Low power magnification of toluidine stained ON cross-sections (0.5 µm). D: Naive control. Axonal bundles (AxB) are evenly
distributed over the surface, with thin axonal septae (s). E-F: ONs from rAION induced estrogen-treated (E) and vehicle treated (F) animals.
There is a marked central loss of axons with increased septal thickness, and shrinkage of the axonal bundles (AxB). The majority of intact
axons are present peripherally, with the greatest loss centrally. G-I: High power magnification of toluidine stained ON cross-sections (0.5 µm)
from naive control (G), estrogen-treated animal (H), and vehicle-treated control (I) ONs show tightly packed myelinated axons (arrow) with
thin septae. ONs from estrogen and vehicle-treated rAION induced animals show axonal loss and ON central scarring, demonstrable as
increased septal thickening (arrowheads), with intact peripheral axons (arrow) and reduction in axonal bundle size. The scale bar represents 50
µm.
1923compared with contralateral control (naive) eyes (Figure 3,
estrogen). A similar RGC loss was seen in vehicle-treated ani-
mals as, compared with contralateral naive control eyes (Fig-
ure 3, compare rAION and control results in the vehicle group).
There was an average 65% loss of RGCs in estrogen-treated
animals and 70% RGC loss in vehicle treated animals. This
difference is not statistically significant (p<0.15; Wilcoxon
rank sum test).
DISCUSSION
 Following rodent ON stroke, both early (1 day) and later reti-
nal gene expression changes occur [7], suggesting that iso-
lated axonal ischemia causes a variety of changes in the RGC
neuron and its surroundings. We hypothesized that genes whose
relative expression alter after estrogen administration, and
which also rapidly change their activity following ON infarct,
could implicate estrogen-associated neuroprotective processes
in the retina. The retina is an estrogen target [23]. Genes sen-
sitive to estrogen administration are likely to be crucial in the
early post-stroke period. Genes fulfilling these criteria include
three RGC-expressed genes, HSC70, HSP90 α, and Brn3b
[24-26], which we previously demonstrated rapidly change
following rAION induction [7].
We also previously identified a rapid post-rAION increase
in the retinal expression of estrogen-enhanced transcript-1
(EET-1; data not shown). EET-1 plays an important role in
increasing levels of tumor necrosis factor α and other inflam-
matory cytokines [21], suggesting that estrogen could regu-
late post-rAION associated inflammation, by modulating tu-
mor necrosis factor-alpha associated glial and microglial in-
flammatory processes that are important in reducing post-
stroke morbidity [27,28]. However, we also determined that
retinal EET-1 expression is not estrogen responsive (data not
shown), suggesting that in the CNS and retina, estrogen does
not modulate the inflammatory roles of EET-1 following inf-
arct. These data, coupled with previous reports of estrogen-
associated neuroprotection following retinal ischemia [20], and
our earlier sighting study, supported our rationale for evaluat-
ing estrogen’s potential as a neuroprotectant after axonal inf-
arct.
It is possible that sex-related differential gene expression
could result in sex associated differences in estrogen-related
neuroprotection. However, estrogen receptors and EET-1 are
both expressed at significant levels in male retinas [29]. EET-
1 is also not estrogen-responsive in female CNS [30], which
suggests that the current findings are not likely to be sex-di-
chotomous.
This study utilized ovariectomized animals, with estro-
gen administered post-stroke. Numerous trials have demon-
strated that estrogen can have neuroprotective effects when
given for a sufficiently long time prior to CNS insult, but a
prior treatment approach is unlikely to be useful for clinical
stroke therapeutics, which typically utilize therapy after the
insult. Additionally, recent studies have not demonstrated that
exogenous estrogen administration improves incidence or
morbidity in stroke [31]. Thus, it is unlikely that estrogen is
significantly neuroprotective when given after CNS axonal
infarction in either male or female animals.
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Figure 3. Stereological analysis
after rodent anterior ischemic op-
tic neuropathy induction retinal
ganglion cell loss in estrogen- and
vehicle-treated animals.  Immedi-
ately after rodent anterior is-
chemic optic neuropathy (rAION)
induction, animals received an in-
tramuscular injection of either 50
µg/kg 17-estradiol, or vehicle
(sesame oil) as described in Meth-
ods. Retinal ganglion cells
(RGCs) were retrograde-labeled
with fluorogold, and animals
euthanized 28 days post-induc-
tion. Retinas were post-fixed, flat
mounted and analyzed as de-
scribed in Methods. A 65% aver-
age RGC loss is seen in estrogen
treated animals, compared with a
70% RGC loss in vehicle treated
animals. Control eyes: contralat-
eral (naíve) eyes from each treat-
ment group. Red bars indicate the
mean RGC count for each group.
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